Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics.
Proteomic pattern diagnostics is a rapidly evolving field of science. Despite the increasingly large number of laboratories reporting exciting success with this concept, recent speculation concerning reproducibility and the nature and identities of the information content of the pattern constituents have served to defocus and polarize the community. These controversies will be rendered obsolete as the field accelerates into a new realm of clinical diagnostics. This new era will see the currently dry biomarker pipeline flooded with new candidate molecules, and the mass spectrometer will continue its maturation into a dominant clinical platform. We reflect on the important lessons gleaned from the Wright brothers' attempts at controlled heavier-than-air flight as a model for perseverance and a view to the very near future for proteomic pattern diagnostics.
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, CBER, FDA, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Emanuel F
EF
Petricoin
David A
DA
Fishman
Thomas P
TP
Conrads
Timothy D
TD
Veenstra
Lance A
LA
Liotta
D015415:Biomarkers; D019937:Diagnostic Techniques and Procedures; D006801:Humans; D040901:Proteomics
D015415:Biomarkers